In a randomized, double-blind, placebo-controlled trial, tesamorelin reduced liver fat and was associated with less fibrosis progression, and a targeted proteomic and transcriptomic analysis of that trial showed the drug lowered fibro-inflammatory mediators including VEGFA, TGF-1, and CSF1
Beyond its relevance to NPH, this work illustrates how CSF-based molecular profiling can provide insight into biological determinants of neurological recovery
Our best advice is to stick with it, as itll benefit you in the long run for sure
,,YingL,ChunhaiH,LeiL,HaiguangZ,WeinaZLongbinMet al.The Role of Oxidative Stress in the Development and Therapeutic Intervention of Hepatocellular Carcinoma.2023;23(10):792804